Mytolac® Indications
ENTEROPANCREATIC-NETS AND CARCINOID SYNDROME1
Grade 1
Well differentiated
Grade 2
Moderately differentiated
Adapted from the National Cancer Institute.
- MYTOLAC® is indicated in the treatment of enteropancreatic neuroendocrine tumours (NETs) in adult patients with Grade 1 or a subset of Grade 2 (equivalent to Ki67 <10%) unresectable, locally advanced or metastatic disease, to delay progression
- The treatment of adult patients with carcinoid syndrome
Mytolac® Indications
Acromegaly
Pituitary tumour
- MYTOLAC® is indicated in the long-term treatment of adult patients with acromegaly due to pituitary tumours who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy
- The relief of symptoms associated with acromegaly